Trial Profile

Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 04 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Aug 2025 According to a DiaMedica Therapeutics media release, the Company expects to complete the interim analysis on the first 200 patients in the second quarter of 2026.
14 May 2025 According to a DiaMedica Therapeutics media release, data from this trial will be presented at the 11th European Stroke Organisation Conference ESOC 2025 , DiaMedica will also be exhibiting at the conference located in the exhibition hall at booth D4.1.
14 May 2025 According to a DiaMedica Therapeutics media release, the interim analysis on the first 200 patients is anticipated to be completed in the first half of 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com